Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $15

Benzinga Newsdesk www.benzinga.com Negative 82.3%

Neg 82.3% Neu 0% Pos 0%

Benchmark analyst Bruce D. Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and lowers the price target from $21 to $15.